Trial Profile

Randomized Observer-Blinded Phase 2 Trial of COVID-19 Booster With GEO-CM04S1 or mRNA Vaccine in Patients With Chronic Lymphocytic Leukemia

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GEO CM04S1 (Primary) ; Tozinameran
Indications COVID 2019 infections
Focus Therapeutic Use

Most Recent Events

28 Aug 2024 According to GeoVax Labs media release, company secure up to $45 million in funding to advance the development of GEO-CM04S1
01 Feb 2024 Planned End Date changed from 9 Jan 2024 to 12 Jan 2026.
01 Feb 2024 Planned primary completion date changed from 9 Jan 2024 to 12 Jan 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com